The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States
Open accessAbstract
BACKGROUND: The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. METHODS: We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma. RESULTS: While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. CONCLUSIONS: It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Cited by
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020) · Pathogens · doi:10.3390/pathogens9030231 · Cited by 775
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
Self-citationPersistence of Ebola Virus in Ocular Fluid during Convalescence
Varkey, J. B., Shantha, J. G., Crozier, I., Kraft, C. S., Lyon, G. M., Mehta, A. K., Kumar, G., Smith, J. R., Kainulainen, M. H., Whitmer, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500306 · Cited by 470
Self-citationThe Pathogenesis of Ebola Virus Disease
Baseler, L., Chertow, D. S., Johnson, K. M., Feldmann, H., & Morens, D. M. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100506 · Cited by 404
Clinical Management of Ebola Virus Disease in the United States and Europe
Uyeki, T. M., Mehta, A. K., Davey, R. T., Liddell, A. M., Wolf, T., Vetter, P., Schmiedel, S., Grünewald, T., Jacobs, M., Arribas, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504874 · Cited by 368
Self-citationKruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.1 · Cited by 311
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
Roback, J. D., & Guarner, J. (2020) · JAMA · doi:10.1001/jama.2020.4940 · Cited by 299
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Zhou, G., & Zhao, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45123 · Cited by 266
Brainard, J., Pond, K., Hooper, L., Edmunds, K., & Hunter, P. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004475 · Cited by 65
Metadata
- Authors
- Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., Varkey, J. B., Mehta, A. K., Lyon, G. M., Friedman-Moraco, R. J., Marconi, V. C., Hill, C. E., Sullivan, J. N., Johnson, D. W., Lisco, S. J., Mulligan, M. J., Uyeki, T. M., McElroy, A. K., Sealy, T., Campbell, S., Spiropoulou, C., Ströher, U., Crozier, I., Sacra, R., Connor, M. J., Sueblinvong, V., Franch, H. A., Smith, P. W., & Ribner, B. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-22
- Volume
- 61
- Issue
- 4
- Pages
- 496-502
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2232354415
- Cited by
- 195
- References
- 1
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.